よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (54 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
126. Ramsey C, et al. A review of the pharmacokinetics and pharmacodynamics of
aztreonam. J Antimicrob Chemother. 2016. 71(10):2704-2712.
3
4
5
127. Moriyama B, et al. High-dose continuous infusion β-lactam antibiotics for the treatment
of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann
Pharmacother. 2010. 44(5):929-935.
6
7
8
128. Vinks AA, et al. Pharmacokinetics of aztreonam in healthy subjects and patients with
cystic fibrosis and evaluation of dose-exposure relationships using monte carlo
simulation. Antimicrob Agents Chemother. 2007. 51(9):3049-3055.
9
10
129. Tamma PD, et al. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam
Resistance. Clin Infect Dis. 2021. 73(11):e4599-e4606.
11
12
130. 厚生労働省 薬剤耐性アシネトバクター感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-140912-4.html.)
13
14
131. Peleg AY, et al. Acinetobacter baumannii: emergence of a successful pathogen. Clin
Microbiol Rev. 2008. 21(3):538-582.
15
16
132. Wong D, et al. Clinical and Pathophysiological Overview of Acinetobacter Infections: a
Century of Challenges. Clin Microbiol Rev. 2017. 30(1):409-447.
17
18
133. Karageorgopoulos DE, et al. Current control and treatment of multidrug-resistant
Acinetobacter baumannii infections. Lancet Infect Dis. 2008. 8(12):751-762.
19
20
134. Falagas ME, et al. Community-acquired Acinetobacter infections. Eur J Clin Microbiol
Infect Dis. 2007. 26(12):857-868.
21
22
23
135. Asai N, et al. Clinical manifestations and risk factors of community-onset Acinetobacter
species pneumonia in Japan; case control study in a single institute in Japan. J Infect
Chemother. 2019. 25(8):639-642.
24
25
136. https://iris.who.int/bitstream/handle/10665/376776/9789240093461eng.pdf?sequence=1
26
27
28
137. WHO priority pathogens list for R&D of new antibiotics. 2017. at
https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-newantibiotics-are-urgently-needed.)
29
30
138. 韓国からの持ち込み例を端緒とした多剤耐性 Acinetobacter baumannii によるアウトブ
レイク事例. IASR. 2010. 31(7):197-198. at http://idsc.nih.go.jp/iasr/31/365/dj3654.html.)
31
32
139. Tojo M, et al. Multidrug-resistant Acinetobactor baumannii isolated from a traveler
returned from Brunei. J Infect Chemother. 2015. 21(3):212-214.
33
34
140. 医療機関における海外からの高度薬剤耐性菌の持ち込み対策に関するガイダンス. DCC.
2019. at https://dcc.ncgm.go.jp/prevention/resource/resource05.pdf.)
35
36
37
141. Pailhoriès H, et al. Using Vitek MALDI-TOF mass spectrometry to identify species
belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex: a
relevant alternative to molecular biology? Diagn Microbiol Infect Dis. 2015. 83(2):99-104.
38
39
40
142. Pailhoriès H, et al. Using Vitek MALDI-TOF mass spectrometry to identify species
belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex: a
relevant alternative to molecular biology? Diagn Microbiol Infect Dis. 2015. 83(2):99-104.
41
42
43
143. Higgins PG, et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J
Antimicrob Chemother. 2010. 65(2):233-8. Erratum in: J Antimicrob Chemother. 2010
Jun;65(6):1317.
44
45
144. Evans BA, et al. OXA β-lactamases. Clin Microbiol Rev. 2014 Apr;27(2):241-63. doi:
10.1128/CMR.00117-13.
54
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
126. Ramsey C, et al. A review of the pharmacokinetics and pharmacodynamics of
aztreonam. J Antimicrob Chemother. 2016. 71(10):2704-2712.
3
4
5
127. Moriyama B, et al. High-dose continuous infusion β-lactam antibiotics for the treatment
of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann
Pharmacother. 2010. 44(5):929-935.
6
7
8
128. Vinks AA, et al. Pharmacokinetics of aztreonam in healthy subjects and patients with
cystic fibrosis and evaluation of dose-exposure relationships using monte carlo
simulation. Antimicrob Agents Chemother. 2007. 51(9):3049-3055.
9
10
129. Tamma PD, et al. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam
Resistance. Clin Infect Dis. 2021. 73(11):e4599-e4606.
11
12
130. 厚生労働省 薬剤耐性アシネトバクター感染症. at
https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou11/01-05-140912-4.html.)
13
14
131. Peleg AY, et al. Acinetobacter baumannii: emergence of a successful pathogen. Clin
Microbiol Rev. 2008. 21(3):538-582.
15
16
132. Wong D, et al. Clinical and Pathophysiological Overview of Acinetobacter Infections: a
Century of Challenges. Clin Microbiol Rev. 2017. 30(1):409-447.
17
18
133. Karageorgopoulos DE, et al. Current control and treatment of multidrug-resistant
Acinetobacter baumannii infections. Lancet Infect Dis. 2008. 8(12):751-762.
19
20
134. Falagas ME, et al. Community-acquired Acinetobacter infections. Eur J Clin Microbiol
Infect Dis. 2007. 26(12):857-868.
21
22
23
135. Asai N, et al. Clinical manifestations and risk factors of community-onset Acinetobacter
species pneumonia in Japan; case control study in a single institute in Japan. J Infect
Chemother. 2019. 25(8):639-642.
24
25
136. https://iris.who.int/bitstream/handle/10665/376776/9789240093461eng.pdf?sequence=1
26
27
28
137. WHO priority pathogens list for R&D of new antibiotics. 2017. at
https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-newantibiotics-are-urgently-needed.)
29
30
138. 韓国からの持ち込み例を端緒とした多剤耐性 Acinetobacter baumannii によるアウトブ
レイク事例. IASR. 2010. 31(7):197-198. at http://idsc.nih.go.jp/iasr/31/365/dj3654.html.)
31
32
139. Tojo M, et al. Multidrug-resistant Acinetobactor baumannii isolated from a traveler
returned from Brunei. J Infect Chemother. 2015. 21(3):212-214.
33
34
140. 医療機関における海外からの高度薬剤耐性菌の持ち込み対策に関するガイダンス. DCC.
2019. at https://dcc.ncgm.go.jp/prevention/resource/resource05.pdf.)
35
36
37
141. Pailhoriès H, et al. Using Vitek MALDI-TOF mass spectrometry to identify species
belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex: a
relevant alternative to molecular biology? Diagn Microbiol Infect Dis. 2015. 83(2):99-104.
38
39
40
142. Pailhoriès H, et al. Using Vitek MALDI-TOF mass spectrometry to identify species
belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex: a
relevant alternative to molecular biology? Diagn Microbiol Infect Dis. 2015. 83(2):99-104.
41
42
43
143. Higgins PG, et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J
Antimicrob Chemother. 2010. 65(2):233-8. Erratum in: J Antimicrob Chemother. 2010
Jun;65(6):1317.
44
45
144. Evans BA, et al. OXA β-lactamases. Clin Microbiol Rev. 2014 Apr;27(2):241-63. doi:
10.1128/CMR.00117-13.
54